VivoSeq
Other

Xerostomia

25

Pipeline Programs↗

8

Active Trials↗

11

Companies Involved↗

Xerostomia is an emerging landscape with 25 programs across 11 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Horizon Therapeutics Ireland DAC, TorreyPines Therapeutics. 5 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

81/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 1H

Horizon Therapeutics Ireland DAC

1 program

Phase 1T

TorreyPines Therapeutics

1 program

Phase 2R

Rohto Pharmaceutical Co., Ltd.

1 program

Phase 2S

Shanghai IxCell Biotechnology Co., LTD

1 program

Phase 2G

Gynecologic Oncology Group

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical3

Hibiscus Sabdariffa

Ain Shams University

Neutrasal

Medical University of South Carolina

Malic Acid

The First Affiliated Hospital of Xinxiang Medical College

Phase 15

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Interferon Gamma-1b

Horizon Therapeutics Ireland DAC

Gel Xerostomia

Universidad de Murcia

D-Limonene Gelcaps

Stanford University

Allogeneic Mesenchymal Stromal Cells

Ottawa Hospital Research Institute

Phase 29

Mesenchymal Stem Cell

Rohto Pharmaceutical Co., Ltd.

Amifostine Trihydrate

Gynecologic Oncology Group

Stem Cells

Kang Stem Biotech Co., Ltd.

Isotonic Nacl

Hvidovre University Hospital

Hypozalix Spray (artificial Saliva)

Shiraz University of Medical Sciences

Phase 33

Aloevera

Government Dental College and Research Institute, Bangalore

Thyme Honey

Ain Shams University

Salagen

Alberta Health services

Approved5

Pilocarpine

Advanz Pharma

Amifostine

Legacy Health System

Dexamethasone

Aspen Global Incorporated

Biotene

University of Southern California

Cevimeline

Cosette Pharmaceuticals, Inc.

Analysis

Modality Breakdown

84%

Small molecule

27 of 32 classified programs — the dominant modality here.

16%ALL OTHERSCell therapy413%Gene therapy13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 97% of 39 pipeline programs.

Analysis

Trial Status

34

clinical trials

Completed13 · 38%
Unknown status10 · 29%
Recruiting4 · 12%
Not yet recruiting4 · 12%
Withdrawn2 · 6%
Terminated1 · 3%

Clinical Trials

Trial Activity

34 trials

The Efficacy of Hibiscus Sabdariffa in Xerostomia
Recruiting·—·N/A·NCT06413550·40 enrolled
d-Limonene +Radiation +PlatinumBasedChemo for Xerostomia Prevention in LocallyAdvanced HNSCC
Recruiting·SStanford University·Phase 1·NCT04392622·40 enrolled
Intraglandular Treatment With Adipose-derived Mesenchymal Stem Cells in Patients With Xerostomia Due to Sjögren's Disease
Recruiting·—·Phase 1/2·NCT06805448·40 enrolled
UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
Recruiting·UUniversity of Wisconsin, Madison·Phase 1·NCT06392711·36 enrolled
Artificial Saliva Containing Cumin and Ginger Extract in Hemodialysis Patients With Xerostomia
Not yet recruiting·—·N/A·NCT06476223·26 enrolled
Repeated Mesenchymal Stem Cell Therapy for Radiation-Induced Hyposalivation and Xerostomia in Head and Neck Cancer Survivors
Not yet recruiting·—·Phase 2·NCT07290946·100 enrolled
Safety and Potential Effect of Innovative Cell-based Therapy Using Adipose-derived Stromal Vascular Fraction in Patients With Autoimmune Xerostomia
Not yet recruiting·AAssistance Publique Hopitaux De Marseille·Phase 1/2·NCT05857358·18 enrolled
A Pilot Randomised Trial Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers
Not yet recruiting·NNational University Hospital, Singapore·Preclinical·NCT07674706·50 enrolled
Efficacy of Traditional Persian Medicine Preparation Versus Artificial Saliva for Radiation Induced Xerostomia
Completed·SShiraz University of Medical Sciences·Phase 2·NCT02854358·60 enrolled
Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome
Completed·TTorreyPines Therapeutics·Phase 2·NCT00637793·24 enrolled
A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia
Completed·MMeiraGTx UK II Ltd·Phase 1·NCT04043104·24 enrolled
The Efficacy of Thyme Honey Mouth Rinse on Polypharmacy-induced Xerostomia
Completed·—·Phase 4·NCT06201923·32 enrolled
NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy
Completed·MMedical University of South Carolina·N/A·NCT02107300·32 enrolled
Effectiveness of Thyme Honey in Management of Xerostomia in Post Radiation Cancer Patients
Completed·—·Phase 4·NCT05859711·90 enrolled
Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Completed·UUniversidad de Granada·Phase 2/3·NCT01652001·185 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)